logo

Sangamo Biosciences Inc (SGMO)



Trade SGMO now with
  Date
  Headline
9/30/2019 4:54:12 PM Sangamo Therapeutics Appoints Bettina Cockroft As SVP And Chief Medical Officer
8/12/2019 7:42:55 AM Wedbush Is Cutting Sangamo Biosciences Inc (SGMO) FY20 Rev. Estimate To 55.1 M From 74.2 M
8/12/2019 7:42:39 AM Wedbush Is Cutting Sangamo Biosciences Inc (SGMO) Q4 20 Rev. Estimate To 9.5 M From 14.2 M
8/12/2019 7:42:29 AM Wedbush Is Lowering Sangamo Biosciences Inc (SGMO) Q3 20 Rev. Estimate To 9.2 M From 14.0 M
8/12/2019 7:42:16 AM Wedbush Is Cutting Sangamo Biosciences Inc (SGMO) Q2 20 Rev. Estimate To 9.2 M From 14.0 M
8/12/2019 7:41:57 AM Wedbush Is Cutting Sangamo Biosciences Inc (SGMO) Q1 20 Rev. Estimate To 27.2 M From 32.0 M
8/12/2019 7:41:29 AM Wedbush Is Lowering Sangamo Biosciences Inc (SGMO) FY19 Rev. Estimate To 61.3 M From 100 M
8/12/2019 7:38:44 AM Wedbush Is Lowering Sangamo Biosciences Inc (SGMO) Q4 19 Rev. Estimate To 18.9 M From 32.2 M
8/12/2019 7:37:51 AM Wedbush Is Cutting Sangamo Biosciences Inc (SGMO) Q3 19 Rev. Estimate To 16.9 M From 30.2 M
8/12/2019 7:36:25 AM Wedbush Is Cutting Sangamo Biosciences Inc (SGMO) FY20 Estimate To -1.34 From -1.17
8/12/2019 7:36:06 AM Wedbush Is Cutting Sangamo Biosciences Inc (SGMO) Q4 20 Estimate To -0.38 From -0.33
8/12/2019 7:35:58 AM Wedbush Is Cutting Sangamo Biosciences Inc (SGMO) Q3 20 Estimate To -0.38 From -0.33
8/12/2019 7:35:35 AM Wedbush Is Lowering Sangamo Biosciences Inc (SGMO) Q2 20 Estimate To -0.37 From -0.33
8/12/2019 7:35:21 AM Wedbush Is Cutting Sangamo Biosciences Inc (SGMO) Q1 20 Estimate To -0.21 From -0.17
8/12/2019 7:35:02 AM Wedbush Is Lowering Sangamo Biosciences Inc (SGMO) FY19 Estimate To -1.20 From -0.92
8/12/2019 7:34:48 AM Wedbush Is Cutting Sangamo Biosciences Inc (SGMO) Q4 19 Estimate To -0.26 From -0.17
8/12/2019 7:34:35 AM Wedbush Is Cutting Sangamo Biosciences Inc (SGMO) Q3 19 Estimate To -0.28 From -0.18
8/12/2019 7:33:35 AM Wedbush Reiterates Sangamo Biosciences Inc (SGMO) At Neutral With $11 Price Target
5/8/2019 4:03:07 PM Sangamo Therapeutics Q1 Loss/share $0.41 Vs. Loss $0.23 Year Ago
  
 
>